Dasatinib

Post Date:
Jul 04,2015
Expiry Date:
Dec 31,2015
Detailed Description:
Cas No. :302962-49-8 Dasatinib is approved to treat:

Acute lymphoblastic leukemia that is Philadelphia chromosome positive in patients who are not able to use other drugs.
Chronic myelogenous leukemia that is Philadelphia chromosome positive. It may be used in patients who are not able to use other drugs.
Dasatinib is also being studied in the treatment of other types of cancer.

Dasatinib is a tyrosine kinase inhibitor. It works by blocking proteins that cause the rapid growth of certain types of leukemia cells. This helps the bone marrow to start making normal blood cells again.
CAS Registry Number:
302962-49-8
Synonyms:
;intermediate;N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide hydrate (1:1);BMS 354825;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;
Molecular Formula:
C₂₂H₂₈ClN₇O₃S
Molecular Weight:
506.0208
Molecular Structure:

Offter to Sell